DeutschNewstral
Article
Mmarketwatch.com on 2022-05-03 18:51
Beset by challenges with its Alzheimer's disease drug, Biogen pivots3 min read
Related news
- MOne Alzheimer's drug has failed, but investors are still betting on Biogen and Lilly treatments 2 min readmarketwatch.com
- MBiogen shares rise 4% before release of Alzheimer's disease trial resultsmarketwatch.com
Biogen shares soar as FDA reviewers support Alzheimer's drugSydney Morning Herald- BBiogen Stock Can Go 'Decisively Higher' on Sales of Alzheimer's Drug2 min readbarrons.com
- BBiogen Stock Drops as Results Fall Short. Sales of Alzheimer's Drug Disappoint.3 min readbarrons.com
- BBiogen to Eliminate Alzheimer's Drug Infrastructure, Search for New CEO1 min readbarrons.com
- MBiogen and Eisai make plans to take another Alzheimer's drug to the FDA3 min readmarketwatch.com
- BBiogen Searches for New CEO in Wake of Struggles With Alzheimer's Drug 4 min readbarrons.com
Change at the top for Biogen after Alzheimer's drug flops - Tue, 03 May 2022 PSTapnews.com
Biogen cutting cost of Alzheimer's drugArkansas Online
Biogen Drug Could Inspire New Hope For Alzheimer'sForbes- MBiogen shares down 9% after Alzheimer's trial resultsmarketwatch.com
Biogen reanalyzes studies, presses ahead on Alzheimer's druglasvegassun.com
Biogen submits US marketing application for Alzheimer's disease drugThe Jerusalem Post (JPost.com)- MBiogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says3 min readmarketwatch.com
- MBiogen earnings: It’s all about upcoming Alzheimer’s disease resultsmarketwatch.com
- Biogen cuts the price tag on its Alzheimer's drug in half - Mon, 20 Dec 2021 PSTapnews.com
Biogen applies to market Alzheimer’s disease treatment in the USNew York Post- BBiogen Announces New Trial for Alzheimer’s drug Aduhelm2 min readbarrons.com